Can a nickel-allergic dermatitis be prevened with a nickel-barrier creme?

Project: Research

Description

The frequency of nickel-allergic women in the general population is around 15-20%. An even higher frequency of nickel allergy has been shown to exist in studies in the age groups where hand eczema commonly develops. Once developed hand dermatitis is a major threat to the individual's ability to perform their work. From Denmark it has been shown that contact allergic hand dermatitis caused by nickel allergy is the most common skin disease resulting in permanent disability. This leads to high costs for the social security system and great suffering for those affected.
The current method of treating nickel allergic eczema is to prescribe cortisone cream, give or prescribe phototherapy or immunosuppression and to advise the patients to avoid nickel which in practice is not easy due to the wide presence of nickel in the environment.
The PhD student in this project has developed a barrier cream against nickel-induced contact dermatitis containing a strong chelating agent DTPA (diethylenetriamine pentaacetic acid) and another chelating agent Chitosan, which is also anti-inflammatory. A study on a small number of patients showed a clear effect when patch testing patients with nickel allergy and not getting any test eczemas where the cream had been applied. The aim of the project is to investigate the cream's effect on nickel-induced eczema, including examining hand eczema in various professions when the cream or placebo cream is given and to investigate how much the cream blocks the nickel allergic dermatitis when patch testing.

Layman's description

The frequency of nickel-allergic women in the general population is around 15-20%. An even higher frequency of nickel allergy has been seen in the age groups where hand eczema commonly develops. Once developed hand dermatitis is a major threat to the individual's ability to perform their work. From Denmark it has been shown that contact allergic hand dermatitis caused by nickel allergy is the most common skin disease resulting in permanent disability. This leads to high costs for the social security system and great suffering for those affected.
The current method of treating nickel allergic eczema is to prescribe cortisone cream, give or prescribe phototherapy or immunosuppression and to advise the patients to avoid nickel which in practice is not easy due to the wide presence of nickel in the environment.
The PhD student in this project has developed a barrier cream against nickel-induced contact dermatitis containing a strong chelating agent DTPA (diethylenetriamine pentaacetic acid) and another chelating agent Chitosan. A study on a small number of patients showed a clear effect when patch testing patients with nickel allergy and not getting any test eczemas where the cream had been applied. The aim of the project is to investigate the cream's effect on nickel-induced eczema, including examining hand eczema in various professions when the cream or placebo cream is given and to investigate how much the cream blocks the nickel allergic dermatitis when patch testing.
Short titlePrevention of nickeldermatitis
StatusActive
Effective start/end date2010/11/01 → …

Participants